COHANCE share price, P/E, ROE & financials

On 6 Nov 2026, Cohance Lifesciences was priced at ₹433.55, or 364.3× trailing earnings, against an industry P/E of 28.7×, and the shares are 39% below their 52-week high. Sales grew 18% a year over 3 years while net profit fell 24%; its ROCE of 4.8% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. It carries very little debt. It is a small-cap company with a market cap of ₹16,589 Cr, ranked 27th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 40% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹440.00
Day high: ₹443.65
Day low: ₹425.00
Prev. close: ₹449.00
Volume: 7.9 L

Health check

1 good · 1 fair · 4 to check

ReturnsBehind
−39.5% over a year, better than 0 of 7 peers.
Price tagPricier
P/E 364.3 vs industry 28.7.
GrowthSteady
Sales +18.3%, profit −24.2% a year over 3 years.
ProfitabilityWeak
ROCE 4.8% vs peer median 17.9%.
Balance sheetSolid
Debt 0.10× equity, interest covered 7.0×, Piotroski 6 of 9.
Red flags5 to check
Return on equity is low at 4.7%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹16,589 Cr, #27 of 154 in its industry by size.

Defensive

Beta 0.59 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹2,142 Cr · profit ₹106 Cr

Market cap: ₹16,589 Cr; Small cap
P/E: 364.3; Industry 28.7
Price to book: 4.25; Peers 4.99
Dividend yield: 0.00%
ROE: 4.7%; Peers 14.7%
ROCE: 4.8%; Peers 17.9%
Debt to equity: 0.10; Debt ₹400 Cr
EPS (TTM): ₹1.19; Face value ₹1
OPM (TTM): 13.9%; Net margin 5.0%
Sales growth: −23.1%; Latest quarter vs a year ago
Profit growth: −149.3%; Latest quarter vs a year ago
Price to sales: 7.75; EV/EBITDA 53.0

Strengths

Practically debt-free.
Positive operating cash flow in each of the last 4 years.

Risks to check

Return on equity is low at 4.7%.
Quarterly profit down 149.3% on a year ago.
Quarterly sales down 23.1% on a year ago.
P/E of 364.3 against an industry P/E of 28.7.
39% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising…

Headquarters: Hyderabad
Sector: Healthcare
ISIN: INE03QK01018
Website: cohance.com

Price range

52 weeks

₹266.70₹715.00

Today

₹425.00₹443.65

Avg volume (3M): 10.7 L
1-year return: minus 39.5%
From 52-week high: minus 39.4%

Analyst consensus

10 analysts

HoldMean target ₹514.00 18.6%

Target range, with today’s price

Low ₹315.00High ₹1,150.00

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
COHANCECohance Lifesciences	433.55	minus 3.44%	16,589	364.3	4.25	4.8%	4.7%	13.9%	18.3%	−24.2%	0.00%	minus 39.5%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
549	556	545	619	422
437	435	449	539	421
112	121	95.4	80.3	1.2
20.4%	21.8%	17.5%	13.0%	0.3%
14.2	15.6	6.2	16.5	12.3
10.2	8.8	9.1	9.2	6.7
45.1	44	46.9	51.2	49.5
−8.1	–	−4.9	−16.5	–
62.8	83.8	40.6	19.9	−42.9
26.1%	20.7%	28.5%	58.3%	−5.4%
48.9	74.1	36.7	19.6	−24.1
1.27	1.92	0.96	0.50	-0.65

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +18.3%
Profit CAGR 3Y: −24.2%
EPS CAGR 3Y: −33.8%
ROE: 4.7%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
1,331	1,034	2,526	2,204
–	minus 22.3%	+144.3%	minus 12.8%
758	625	1,696	1,769
573	409	830	435
43.0%	39.6%	32.9%	19.7%
28.2	16.5	20.1	10.5
12.8	7	38	34.6
46.5	54.6	167	187
18	41.7	−3	−16.2
560	406	643	207
26.5%	26.0%	24.6%	27.5%
411	300	487	179
–	minus 27.0%	+62.3%	minus 63.2%
16.16	11.80	12.68	4.68

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
25.5	25.5	25.5	38.3
1,710	2,025	3,623	3,873
70.3	65	486	400
160	139	1,346	1,418
1,966	2,255	5,481	5,730
769	788	2,103	2,170
168	181	338	180
117	131	146	268
484	821	298	320
427	334	2,596	2,792
1,966	2,255	5,481	5,730

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
457	385	673	368
−195	−362	−390	−255
−242	−40	−327	−165
20.2	−17.6	−43.8	−51.4
−286	−51.9	−317	−220
171	333	357	148
−204	–	–	–

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 22.3% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you